Pharmaceutical Investing Auris Medical Receives Positive Scientific Advice from EMA on Development Plan and Regulatory Pathway for AM-111
Pharmaceutical Investing Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple Osteochondromas
Pharmaceutical Investing Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results
Pharmaceutical Investing CytomX Therapeutics Announces Full-Year 2017 Financial Results and Provides Operational Update
Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology
